Chart Industries Strategic Review of BioMedical Oxygen Product Lines

Chart Industries is conducting a strategic review of the oxygen-related product lines within its BioMedical segment, including an evaluation of a possible divestiture. The cryobiological portions of the segment are excluded from the review. No transaction has been announced or consummated.

“We are conducting a strategic review of the oxygen-related product lines within our Biomedical segment, including an evaluation of a possible divestiture of the businesses. We are excluding from the review those portions of the BioMedical segment that utilize and align with our cryogenic technological expertise (Cryobiological).”

Signals are extracted from public coverage and print archives and pinned to a verbatim quote, presented as reported by their sources; naming a company in a signal is not an accusation against it. The verified mark denotes a high-confidence, corroborated signal. See our methodology and legal notes.